STAA
STAAR Surgical Company NASDAQ Listed Feb 24, 1992$29.12
-0.34%
vs $29.22
Mkt Cap $1.4B
52w Low $15.59
66.7% of range
52w High $35.87
50d MA $28.33
200d MA $24.39
P/E (TTM)
-18.0x
EV/EBITDA
—
P/B
4.2x
Debt/Equity
0.1x
ROE
-23.4%
P/FCF
-36.0x
RSI (14)
43.50
ATR (14)
$1.00
Beta
1.04
50d MA
$28.33
200d MA
$24.39
Avg Volume
908.2K
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
25651 Atlantic Ocean Drive · Lake Forest, CA 92630 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | 0.18 | -0.20 | -211.1% | 18.92 | -6.6% | +1.6% | -3.4% | -0.6% | -0.8% | -5.9% | — |
| Nov 5, 2025 | AMC | 0.18 | 0.46 | +155.6% | 25.25 | +0.4% | +5.5% | -0.3% | +3.2% | -0.0% | -5.7% | — |
| Aug 6, 2025 | AMC | -0.56 | -0.07 | +87.5% | 26.90 | +0.0% | +0.2% | +1.2% | +0.1% | +0.3% | +3.0% | — |
| May 7, 2025 | AMC | -0.59 | -0.52 | +11.9% | 19.44 | -5.9% | +0.5% | -0.6% | +4.4% | -6.3% | -8.3% | — |
| Feb 11, 2025 | AMC | 0.02 | -0.50 | -2600.0% | 21.88 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% | — |
| Oct 30, 2024 | AMC | 0.19 | 0.37 | +94.7% | 29.49 | +6.2% | -1.7% | -1.5% | +2.0% | +3.0% | +2.8% | — |
| Aug 7, 2024 | AMC | 0.25 | 0.33 | +32.0% | 36.35 | +12.0% | +11.0% | -4.9% | +0.4% | -4.7% | -4.4% | — |
| May 7, 2024 | AMC | 0.05 | 0.06 | +20.0% | 46.65 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% | — |
| Feb 26, 2024 | AMC | 0.19 | 0.24 | +26.3% | 31.75 | +3.9% | +2.9% | -3.4% | -1.0% | +6.6% | +3.6% | — |
| Nov 1, 2023 | AMC | 0.20 | 0.30 | +50.0% | 43.32 | -10.4% | -16.9% | +5.0% | -8.8% | +1.4% | -3.5% | — |
| Aug 2, 2023 | AMC | 0.32 | 0.40 | +25.0% | 52.30 | -14.0% | -9.6% | +2.3% | -3.5% | +0.3% | -2.9% | — |
| May 3, 2023 | AMC | 0.11 | 0.18 | +63.6% | 70.09 | -1.6% | -7.8% | +4.2% | +0.4% | -1.9% | +1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 | Wedbush | Upgrade | Neutral → Outperform | $40 | $29.40 | $35.77 | +21.7% | +8.9% | +0.2% | +0.7% | +0.9% | +1.4% |
| Apr 9 | Wedbush | Maintains | Neutral → Neutral | — | $20.88 | $24.85 | +19.0% | +20.7% | +4.9% | +1.5% | -9.0% | +1.2% |
| Apr 9 | Canaccord Genuity | Upgrade | Hold → Buy | — | $20.88 | $24.85 | +19.0% | +20.7% | +4.9% | +1.5% | -9.0% | +1.2% |
| Mar 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.22 | $18.93 | -1.5% | -3.4% | -0.6% | -0.8% | -5.9% | +2.5% |
| Mar 4 | Stifel | Maintains | Hold → Hold | — | $18.92 | $17.67 | -6.6% | +1.6% | -3.4% | -0.6% | -0.8% | -5.9% |
| Feb 9 | Stifel | Maintains | Hold → Hold | — | $17.58 | $17.47 | -0.6% | -1.0% | -0.6% | -0.3% | -4.4% | -2.4% |
| Jan 28 | Jefferies | Maintains | Buy → Buy | — | $19.04 | $18.94 | -0.5% | +0.6% | -1.1% | +0.1% | -4.8% | +0.6% |
| Jan 16 | Canaccord Genuity | Maintains | Hold → Hold | — | $20.97 | $20.53 | -2.1% | +0.0% | +0.0% | -1.7% | -3.5% | -3.8% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $25.39 | $23.63 | -6.9% | -5.5% | +2.9% | -2.2% | -2.4% | +5.3% |
| Dec 10 | Canaccord Genuity | Maintains | Hold → Hold | — | $25.39 | $23.63 | -6.9% | -5.5% | +2.9% | -2.2% | -2.4% | +5.3% |
| Aug 7 | Stifel | Downgrade | Buy → Hold | — | $26.90 | $26.90 | +0.0% | +0.2% | +1.2% | +0.1% | +0.3% | +3.0% |
| Aug 6 | Canaccord Genuity | Maintains | Hold → Hold | — | $27.02 | $27.05 | +0.1% | -0.4% | +0.2% | +1.2% | +0.1% | +0.3% |
| Aug 5 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $18.49 | $26.77 | +44.8% | +46.1% | -0.4% | +0.2% | +1.2% | +0.1% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $16.86 | $17.22 | +2.1% | +1.4% | +1.1% | +0.5% | +2.3% | +2.9% |
| May 27 | Canaccord Genuity | Maintains | Hold → Hold | — | $18.68 | $18.96 | +1.5% | +1.3% | -4.4% | +1.4% | -2.8% | -6.3% |
| May 21 | Needham | Maintains | Hold → Hold | — | $19.24 | $19.07 | -0.9% | -4.1% | +1.7% | -0.5% | +1.3% | -4.4% |
| May 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $19.44 | $18.30 | -5.9% | +0.5% | -0.6% | +4.4% | -6.3% | -8.3% |
| Mar 18 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $17.61 | $16.45 | -6.6% | +3.8% | -0.2% | -1.8% | -1.1% | +0.3% |
| Feb 27 | Needham | Maintains | Hold → Hold | — | $17.09 | $16.62 | -2.8% | +3.5% | -1.1% | -5.9% | +7.8% | +2.4% |
| Feb 13 | Canaccord Genuity | Maintains | Hold → Hold | — | $16.48 | $16.32 | -1.0% | -3.2% | -3.8% | +8.3% | +6.9% | -5.2% |
| Feb 12 | William Blair | Downgrade | Outperform → Market Perform | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Piper Sandler | Maintains | Neutral → Neutral | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Needham | Maintains | Hold → Hold | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Stifel | Maintains | Buy → Buy | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Jan 7 | Needham | Maintains | Hold → Hold | — | $23.33 | $23.30 | -0.1% | +2.4% | -3.2% | -0.5% | -2.3% | -3.7% |
| Dec 9 | Canaccord Genuity | Maintains | Hold → Hold | — | $25.31 | $25.87 | +2.2% | +3.8% | +0.6% | -4.5% | +0.6% | -2.1% |
| Nov 1 | Canaccord Genuity | Maintains | Hold → Hold | — | $28.99 | $28.75 | -0.8% | -1.5% | +2.0% | +3.0% | +2.8% | +1.9% |
| Aug 26 | Stifel | Maintains | Buy → Buy | — | $33.27 | $33.05 | -0.7% | -1.7% | -1.0% | -1.4% | +0.7% | +3.0% |
| Aug 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $36.35 | $40.72 | +12.0% | +11.0% | -4.9% | +0.4% | -4.7% | -4.4% |
| Jul 15 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $47.11 | $44.48 | -5.6% | -4.0% | +1.3% | -3.5% | -2.5% | -1.5% |
| Jul 15 | BTIG | Maintains | Buy → Buy | — | $47.11 | $44.48 | -5.6% | -4.0% | +1.3% | -3.5% | -2.5% | -1.5% |
| Jun 11 | BTIG | Upgrade | Neutral → Buy | — | $38.07 | $39.83 | +4.6% | +1.7% | +6.0% | +2.1% | -1.6% | -2.8% |
| May 8 | Mizuho | Maintains | Buy → Buy | — | $46.65 | $45.00 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% |
| May 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $46.65 | $45.00 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% |
| May 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $46.65 | $45.00 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% |
| Apr 11 | Mizuho | Maintains | Buy → Buy | — | $51.08 | $51.81 | +1.4% | +1.0% | -3.5% | -7.2% | +0.9% | -0.6% |
| Apr 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $48.68 | $48.92 | +0.5% | +1.7% | +5.6% | -2.2% | +1.0% | -3.5% |
| Apr 1 | Stifel | Maintains | Buy → Buy | — | $38.28 | $38.95 | +1.8% | +2.0% | +1.3% | -1.2% | +16.5% | +7.0% |
| Mar 11 | Stifel | Upgrade | Hold → Buy | — | $35.86 | $38.58 | +7.6% | +8.1% | -2.9% | +1.4% | -0.3% | -0.8% |
| Feb 28 | Mizuho | Maintains | Buy → Buy | — | $32.68 | $31.97 | -2.2% | -3.4% | -1.0% | +6.6% | +3.6% | -3.5% |
| Feb 27 | Piper Sandler | Maintains | Neutral → Neutral | — | $31.75 | $33.00 | +3.9% | +2.9% | -3.4% | -1.0% | +6.6% | +3.6% |
| Dec 5 | Needham | Downgrade | Buy → Hold | — | $32.29 | $31.17 | -3.5% | -4.6% | -0.6% | +2.4% | +6.6% | -3.8% |
| Nov 2 | Piper Sandler | Maintains | Neutral → Neutral | — | $43.32 | $38.80 | -10.4% | -16.9% | +5.0% | -8.8% | +1.4% | -3.5% |
| Nov 2 | Needham | Maintains | Buy → Buy | — | $43.32 | $38.80 | -10.4% | -16.9% | +5.0% | -8.8% | +1.4% | -3.5% |
| Sep 22 | Stifel | Maintains | Hold → Hold | — | $39.39 | $40.04 | +1.7% | +0.1% | +4.4% | -1.7% | -1.5% | +0.3% |
| Sep 15 | Piper Sandler | Maintains | Neutral → Neutral | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 15 | Mizuho | Maintains | Buy → Buy | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 15 | Needham | Maintains | Buy → Buy | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 15 | Benchmark | Downgrade | Buy → Hold | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
STAAR's Q1 2026 net sales expected to exceed $90 million, more than doubling year-over-year, signaling strong demand for its eye surgery products and justifying a significant upward stock revaluation.
Apr 8
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Without seeing the actual press release content in Exhibit 99.1, I cannot provide specific stock impact analysis, as the "transition described above" is not included in your summary.
Please share the full filing details or the press release text for accurate assessment.
Mar 24
8-K · 7.01
! Medium
Staar Surgical Co -- 8-K 7.01: Regulation FD Disclosure
Staar Surgical will hold a conference call on March 3, 2026 to discuss Q4 and full-year 2025 financial results with interim co-CEOs presenting operational and financial performance.
Mar 3
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
STAAR Surgical's Chief Legal Officer Nathaniel Sisitsky terminated employment effective February 4, 2026, requiring investors to monitor leadership transition implications and potential interim management arrangements.
Feb 5
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
Staar Surgical appoints Warren Foust as CEO effective February 1, 2026, promoting the CFO to Vice President, signaling leadership transition that may affect operational strategy and investor confidence.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Broadwood Capital Inc | 16,123,842 | $302M | Added | Mar 2026 |
| 2 | Yunqi Capital Ltd | 3,257,130 | $61M | Added | Mar 2026 |
| 3 | Morgan Stanley | 1,857,828 | $43M | Added | Dec 2025 |
| 4 | Vanguard Portfolio Management Llc | 2,123,589 | $40M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,690,606 | $32M | New | Mar 2026 |
| 6 | Aqr Arbitrage Llc | 914,573 | $21M | Added | Dec 2025 |
| 7 | Citadel Advisors Llc | 1,059,428 | $20M | Added | Mar 2026 |
| 8 | Point72 Asset Management | 823,152 | $15M | New | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 559,586 | $10M | Added | Mar 2026 |
| 10 | Jane Street Group, Llc | 328,809 | $8M | Added | Dec 2025 |
| 11 | Northern Trust Corp | 400,218 | $7M | Reduced | Mar 2026 |
| 12 | Principal Financial Group Inc | 263,288 | $6M | Added | Dec 2025 |
| 13 | Ai-Squared Management Ltd | 268,084 | $5M | New | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 231,527 | $4M | Reduced | Mar 2026 |
| 15 | Hrt Financial Lp | 220,415 | $4M | New | Mar 2026 |
| 16 | Susquehanna International Group, Llp | 183,052 | $3M | Added | Mar 2026 |
| 17 | Ubs Group Ag | 179,929 | $3M | Reduced | Mar 2026 |
| 18 | Millennium Management | 165,508 | $3M | Reduced | Mar 2026 |
| 19 | Invesco Ltd. | 149,027 | $3M | Reduced | Mar 2026 |
| 20 | Nuveen, Llc | 137,920 | $3M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.45B
Enterprise Value
$1.26B
P/E (TTM)
-17.98x
Forward P/E
74.90x
PEG Ratio
-0.05x
P/B
4.19x
P/S
6.03x
P/FCF
-36.04x
EV/EBITDA
—
Shares Out
49.6M
Financials (TTM)
Revenue
$239.4M
Net Income
-$80.4M
EBITDA
-$37.2M
Free Cash Flow
-$40.0M
Op Cash Flow
-$34.2M
EPS Basic
$-1.62
EPS Diluted
$-1.62
EPS Forward
$0.39
Gross Margin
73.9%
Op Margin
-19.2%
Net Margin
-33.6%
Balance Sheet
Total Assets
$461.6M
Total Liab.
$117.4M
Total Equity
$344.2M
Cash
$187.5M
LT Debt
$0
Book Value/Sh
$6.94
Debt/Equity
0.11x
Current Ratio
4.55
Quick Ratio
3.74
Returns & Growth
ROE
-23.4%
ROA
-17.8%
ROIC
-11.2%
Rev Growth YoY
-23.7%
EPS Growth YoY
-295.1%
Price Returns
2W
-6.6%
1M
+13.4%
3M
+50.2%
6M
+12.6%
12M
+67.8%
Technicals
52W High
$35.87
52W Low
$15.59
50d MA
$28.33
200d MA
$24.39
RSI (14)
43.50
ATR (14)
$1.00
Beta
1.04
Avg Volume
908K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$22.95
High
$30.75
Low
$13.00
Median
$26.00
Data updated apr 27, 2026 3:04am
· Source: financialmodelingprep.com